NetworkNewsBreaks – INmune Bio, Inc. (NASDAQ: IN
Post# of 33
(Total Views: 239)
Posted On: 08/01/2019 5:01:53 PM
NetworkNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) Co-Founder and CEO to Present at Cambridge Healthcare Institute’s Seventh Annual Immuno-Oncology Summit
INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, this morning announced that its Co-Founder and CEO RJ Tesi, M.D. will present at the Cambridge Healthcare Institute’s Seventh Annual Immuno-Oncology Summit. The event is taking place in Boston from August 5 through August 9, 2019, and Dr. Tesi’s presentations will include “Targeting Soluble TNF to Improve Efficacy of Combination Immunotherapy,” “Next-Generation Immunotherapies,” and “Targeting ‘Protector’ Cells of the Innate Immune System.” “We are committed to helping treatment-resistant patients by advancing the clinical development of combination therapies and other effective cancer treatments,” Dr. Tesi said in the news release. “I am delighted to have the chance to present with some of the most prominent leaders in the immuno-oncology community.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, this morning announced that its Co-Founder and CEO RJ Tesi, M.D. will present at the Cambridge Healthcare Institute’s Seventh Annual Immuno-Oncology Summit. The event is taking place in Boston from August 5 through August 9, 2019, and Dr. Tesi’s presentations will include “Targeting Soluble TNF to Improve Efficacy of Combination Immunotherapy,” “Next-Generation Immunotherapies,” and “Targeting ‘Protector’ Cells of the Innate Immune System.” “We are committed to helping treatment-resistant patients by advancing the clinical development of combination therapies and other effective cancer treatments,” Dr. Tesi said in the news release. “I am delighted to have the chance to present with some of the most prominent leaders in the immuno-oncology community.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)